Federal Bid

Last Updated on 03 Oct 2013 at 8 AM
Solicitation
Location Unknown

Proprietary Custom Antibodies, Buffers, and Blocking Reagents

Solicitation ID 3038227
Posted Date 12 Sep 2013 at 6 PM
Archive Date 03 Oct 2013 at 5 AM
NAICS Category
Product Service Code
Set Aside No Set-Aside Used
Contracting Office National Institute On Drug Abuse, Station Support/Simplified Acquisitions
Agency Department Of Health And Human Services
Location United states
The solicitation number is 3038227 and the solicitation is issued as a pre-solicitation notice of intent to award a non-competitive order to Cisbio Bioassays UA, 135 South Road, Bedford, MA, 01730.

This acquisition is conducted under the authority of the Federal Acquisition Regulation (A FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirement of FAR Part 6-Competition Requirements.

The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-69, dated August 1, 2013.

A notice regarding any set-aside restrictions, the associated NAICS code 334516 and the small business size standard 500 employees. This acquisition is being conducted in accordance with the procedures of FAR Part 13-Simplified Acquisition Procedures.

The National Institute on Drug Abuse (NIDA), Station Support/Simplified Acquisition (SS/SA) Branch has a requirement on behalf of National Center for Advancing Translational Science (NCATS) to purchase proprietary custom antibodies, buffers, and blocking reagents. This request will be used to screen the Tox21 10K library with an assay for DNA damage. The assay works by detecting the phosphorylation of histone H2AX by labeling antibodies with donor and acceptor fluors (europium cryptate and d2) to enable homogenous detection in a high throughput environment using Cisbio's HTRF technology. The only technology available for pH2AX detection is immunofluorescence, which requires may incubation and wash steps. HTRF is a homogeneous and non radio-isotopic technology. This HTRF technology has been developed and also successfully used for NCATS online validation for this homogenous (no wash steps) DNA damage detection assay that was just approved by NCATS review group. When DNA double strand breaks occur, histone H2AX is phosphorylated and moves to the site of the damage. This assay will be used in CHO cells as marker for DNA damage. Homogeneous assays, like HTRF, are key to efficient and effective screening. Our Tox21 research group, as well as other NCATS Biology groups, has used this Cisbio HTRF technology for several large screens in 1536 well format, with high reproducibility and low false positives, compared to other technologies. For example, the HTFR TNF alpha assay was used to screen the LOPAC and FDA libraries in 1536 well format with great success. NCATS will use this assay to screen compounds from EPA/NTP/FDA. This is the Tox21 collaboration work between NCGC and NTP/EPA/FDA.

HTRF labeling technology is exclusive to Cisbio as this specific labeling technology, with Europium cryptate and d2 is not available at any other company. In addition, Cisbio holds a patent for using the ratio of the signals for normalization of the assay.

The Defense Priorities and Allocations System (DPAS) is not applicable to this requirement.

The synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov."

All responses must be received by September 18, 2013 12:00PM EST and must reference number 3038227. Responses may be submitted electronically to Jasmine Snoddy, Contract Specialist and email at [email protected] or by U.S. mail to the National Institute of Drug Abuse (NIDA), Station Support/Simplified Acquisition Branch, 31 Center Drive, Room 1B59, Bethesda, Maryland 20892-2080, Attention: Jasmine Snoddy. Fax responses will not be accepted.

"All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."

The name and telephone number of the individual to contact for information regarding the solicitation is Jasmine Snoddy and telephone number is (301) 594-1571.

 

 

Bid Protests Not Available

Similar Past Bids

Location Unknown 01 Aug 2013 at 2 PM
Bethesda Maryland 20 Aug 2009 at 6 PM
Location Unknown 28 Jun 2019 at 1 PM
Center Kentucky 20 Jul 2018 at 5 PM
San diego California 21 May 2018 at 3 PM